Abstract
Pharmacokinetic and pharmacodynamic (PK/PD) analyses for a novel thromboxane synthetase inhibitor, DP-1904, were performed to predict its PK/PD profiles in human after single and repeated oral administration. The pharmacodynamics of DP-1904 was characterized by serum levels of thromboxane B2(TXB2), a pharmacological marker for thromboxane synthetase inhibition. Based on a quantitative relationship between the plasma DP-1904 and serum TXB2 concentrations after single oral dosage, IC50 and Emax values were estimated to be 0.54 ng/ml and 94%, respectively. An integrated, simple PK/PD model was developed to simulate the changes in serum TXB2 levels after single oral administration of DP-1904 at various doses, and the simulation curves corresponded well with the observed data. The PK/PD model was then used to predict a pharmacological profile of DP-1904 after repeated oral doses in human; the predicted curves were in relatively good agreement with the observed data. Thus, it is suggested that our PK/PD model is feasible and practical for developing optimum dosing regimens of DP-1904 in clinical situations.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
